France Acute Myeloid Leukemia Market Report 2023 to 2030

France Acute Myeloid Leukemia Market Analysis

$ 3999

France Acute Myeloid Leukemia Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The ageing population, higher drug approval rates, the designation of acute myeloid leukaemia as an orphan disease, and rising healthcare costs are anticipated to drive the market. One of the factors accelerating the market's growth is the technological advancement made possible by the capacity to recognise damaged cells. Major global players in Acute Myeloid Leukemia Market are Ambit Biosciences Corporation, Genzyme Corporation, Celgene Corporation, Clavis Pharma ASA, Sunesis Pharmaceuticals, Cephalon, Bristol-Myers Squibb, Novartis International AG, GlaxoSmithKline.

ID: IN10FRRD071 CATEGORY: Rare Diseases GEOGRAPHY: France AUTHOR: Nipun Arora

Buy Now

France Acute Myeloid Leukemia Market Analysis Summary

France Acute Myeloid Leukemia Market is valued at around $31.6 Mn in 2022 and is projected to reach $72.99 Mn by 2030, exhibiting a CAGR of 11.03% during the forecast period 2023-2030.

Acute myelogenous leukaemia (AML) is a malignancy of the blood and bone marrow, the spongy tissue found inside bones that is responsible for producing blood cells. The word "acute" in acute myelogenous leukaemia refers to the illness' quick development. Myeloid cells, a subset of white blood cells that typically mature into other types of mature blood cells such red blood cells, white blood cells, and platelets, are what give myelogenous leukaemia its name (my-uh-LOHJ-uh-nus). Other names for acute myelogenous leukaemia include acute granulocytic leukaemia, acute myeloblastic leukaemia, acute nonlymphocytic leukaemia, and acute myeloid leukaemia. Acute myeloid leukaemia (AML) begins in the bone marrow, which is the soft interior of some bones and the site of new blood cell production, but it frequently spreads swiftly into the circulation as well. It can occasionally spread to the lymph nodes, liver, spleen, testicles, central nervous system (brain and spinal cord), and other organs of the body.

The ageing population, higher drug approval rates, the designation of acute myeloid leukaemia as an orphan disease, and rising healthcare costs are anticipated to drive the market. One of the factors accelerating the market's growth is the technological advancement made possible by the capacity to recognise damaged cells. Major global players in Acute Myeloid Leukemia Market are Ambit Biosciences Corporation, Genzyme Corporation, Celgene Corporation, Clavis Pharma ASA, Sunesis Pharmaceuticals, Cephalon, Bristol-Myers Squibb, Novartis International AG, GlaxoSmithKline.

Market Dynamics

Market Drivers

The primary factors driving this market's growth are the high incidence and prevalence of acute myeloid leukaemia, advances in pharmacology and molecular biology to enable drug discovery, and increased pharmaceutical firm investment in research and development. According to the American Cancer Society, there will be 60,650 new instances of leukaemia cancer in the US in 2022, and 24,000 of those cases will result in fatalities. The same source also predicts that in 2022, there will be 20,050 new cases of acute myeloid leukaemia (AML) in the US. The use of AML therapies will increase as a result. It is projected that the rising prevalence of AML in industrialised countries like the US will drive the growth of this market. Furthermore, more clinical studies are being undertaken to show the efficiency of pharmaceuticals as a result of the expanding investment in research and development. It will boost the market.

Market Restraints

The high cost of therapeutic equipment and likely side effects represent a substantial commercial constraint. The market for treatments for Acute Myeloid Leukaemia (AML) encounters challenges due to inconsistent reimbursement policies and stringent product approval regulations.

Key players

Novartis AbbVie Johnson & Johnson Celgene Bristol-Myers Squibb BMS Amgen Sanofi Pfizer Roche

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

France Acute Myeloid Leukemia Market Segmentation

By Chemotherapy:

Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal Therapy
Other Chemotherapies

By Route of Administration:

Oral
Parenteral
Others

By End Users:

Hospitals
Clinics
Specialized treatment centers
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.